Schrodinger (SDGR) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Schrodinger (SDGR) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 27.4% versus a loss of 14.1%. Over five years, VRDN leads with a +7.4% price change compared with -52.3% for SDGR. Viridian Therapeutics is the larger company by market cap ($2.08 billion vs $2.03 billion), about 1.0 times the size.
Schrodinger converts more of its revenue into profit, with a net margin of -40.4% versus -483.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SDGR | VRDN |
|---|---|---|
| Share price | $27.14 | $18.40 |
| Market cap | $2.03B | $2.08B |
| 1-day change | +2.84% | +0.33% |
| YTD return | +47.60% | -41.07% |
| 1-year return | +27.36% | -14.14% |
| 5-year return | -52.33% | +7.44% |
| EPS (TTM) | $-0.74 | $-3.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $255.87M | $70.85M |
| Revenue growth (YoY) | +23.29% | +23359.93% |
| Net income (latest FY) | $-103.27M | $-342.60M |
| Gross margin | 55.74% | — |
| Operating margin | -65.23% | -512.91% |
| Net margin | -40.36% | -483.57% |
| 52-week high | $33.78 | $34.29 |
| 52-week low | $10.95 | $13.18 |
| Distance from 52-week high | -19.66% | -46.34% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -21.03% | +99.73% |
| Average volume | 1.78M | 1.71M |
| Shares outstanding | 65.64M | 113.29M |
| Employees | 850 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SDGR has outperformed VRDN by 41.5 percentage points over the past year.
- Schrodinger is more profitable, keeping -40.4 cents of every revenue dollar as net income versus -483.6 cents for Viridian Therapeutics.
- Viridian Therapeutics grew revenue faster in its latest fiscal year (+23359.93% vs +23.29%).
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
SDGR vs VRDN FAQ
Which is bigger, Schrodinger or Viridian Therapeutics?
Viridian Therapeutics (VRDN) is larger, with a market capitalization of $2.08B compared with $2.03B for Schrodinger (SDGR).
Which stock has performed better over the past year, SDGR or VRDN?
SDGR returned +27.36% over the past 12 months, compared with -14.14% for VRDN (price return, excluding dividends). Past performance does not predict future results.
Are Schrodinger and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.